A new mutational AKTivation in the PI3K pathway
- PMID: 17692802
- DOI: 10.1016/j.ccr.2007.07.014
A new mutational AKTivation in the PI3K pathway
Abstract
Although multiple members of the phosphatidylinositol-3-kinase pathway (PI3K) are targeted by germline or somatic mutations, functional mutations in the three akt isoforms have proven elusive. This is somewhat surprising, as AKT represents a key node in the PI3K pathway, exhibiting transforming activity when incorporated into the AKT8 retrovirus. A recent report in Nature identifies a transforming E17K PH domain mutation in akt1 in breast (8%), colorectal (6%), and ovarian (2%) cancers. E17K-akt1 transforming activity appears due to PtdIns(3,4)P2- and PtdIns(3,4,5)P3-independent recruitment of AKT1 to the membrane. This novel observation raises important theoretical and clinical questions.
Similar articles
-
AKT1(E17K) in human solid tumours.Oncogene. 2008 Sep 18;27(42):5648-50. doi: 10.1038/onc.2008.170. Epub 2008 May 26. Oncogene. 2008. PMID: 18504432
-
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.Oncogene. 2010 Jan 7;29(1):150-5. doi: 10.1038/onc.2009.315. Epub 2009 Oct 5. Oncogene. 2010. PMID: 19802009
-
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.Oncogene. 2008 Jul 3;27(29):4096-106. doi: 10.1038/onc.2008.40. Epub 2008 Mar 3. Oncogene. 2008. PMID: 18317450
-
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.J Urol. 2009 Dec;182(6):2569-77. doi: 10.1016/j.juro.2009.08.085. J Urol. 2009. PMID: 19836781 Review.
-
Drug discovery approaches targeting the PI3K/Akt pathway in cancer.Oncogene. 2008 Sep 18;27(41):5511-26. doi: 10.1038/onc.2008.246. Oncogene. 2008. PMID: 18794885 Review.
Cited by
-
Garcinol-A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug.Int J Mol Sci. 2021 Mar 11;22(6):2828. doi: 10.3390/ijms22062828. Int J Mol Sci. 2021. PMID: 33799504 Free PMC article. Review.
-
Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis.Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20538-20548. doi: 10.1073/pnas.2002964117. Epub 2020 Aug 11. Proc Natl Acad Sci U S A. 2020. PMID: 32788364 Free PMC article.
-
Profiling mTOR pathway in neuroendocrine tumors.Target Oncol. 2012 Sep;7(3):183-8. doi: 10.1007/s11523-012-0226-9. Epub 2012 Aug 14. Target Oncol. 2012. PMID: 22890559 Review.
-
Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival.J Oncol. 2012;2012:416927. doi: 10.1155/2012/416927. Epub 2012 Apr 5. J Oncol. 2012. PMID: 22570651 Free PMC article.
-
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.Oncotarget. 2016 May 17;7(20):29780-93. doi: 10.18632/oncotarget.8957. Oncotarget. 2016. PMID: 27119232 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous